tion, and "oxidative stress" major causes of dementia and AD pathology?
Deborah Blacker: Working primarily in genetics, I think of prevention mainly as using genes to characterize risk/identify a high-risk sample for intervention trials and also to identify protective alleles. However, I was probably asked as an epidemiologist who is beginning to compile a new Alzforum database on AD epidemiology that will summarize available data on risk and protective factors.
David Sinclair: We work on a set of genes called the sirtuins that seems to control the body's defenses against aging and disease. They are activated by caloric restriction, the diet that protects against neurodegenerative disease and aging. We also have small molecules that activate these pathways that can slow disease progression in an AD model -the p25 mouse.
Sam Sisodia: David, would you describe the phenotypes in the AD p25 mouse for me?
David Sinclair: The mice experience severe neurodegeneration 12 weeks after p25 is switched on -along with plaques, tangles, and behavioral/memory defects.
Sam Sisodia: David, plaques and tangles in the p25 mice?
David Sinclair: Sam, this data is early and not from my laboratory, but the p25 model gets more interesting the more is known.
Gabrielle Strobel: Sam, they are Li-Huei Tsai's mice, in which p25 seems to have effects in synaptic biology. Brief induction improves learning; chronic induction leads to neurodegeneration.
Sally Frautschy: I am interested in the differences between the Jankowsky group's [4] and the Sisodia group's [5] data on effects of enriched environment on amyloid. Jankowsky's group got improved function with increased amyloid, but their paradigm had less exercise than Sisodia's group had. What does Sam think?
Sam Sisodia: Sally, 24 female mice in a cage is a formula for stress. . .
David Sinclair:
For all, I suspect most people do not know yet that sirtuin activating compounds (STACs) are proving effective in a number of neurodegenerative disorders, and that this data should come out in 2006. We are testing our transgenic SIRT1 mice for their ability to slow AD, Huntington (HD), Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS).
Lucy Boyd: David, regarding the sirtuins that are activated by caloric restriction, can you describe the level of restriction required for activation? In a normal-weight animal, does this require weight loss beyond a level of normality?
John Trojanowski: David Sinclair, this is puzzling as AD, PD, HD, and so on, all have different underlying mechanisms of disease, and many of us are skeptical that anti-Aβ therapies will ameliorate all neurodegenerative pathways in AD, or tauopathies, so how do STACs work across so many diverse diseases with different etiologies? While all involve aging, there are some hereditary forms of AD and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) that begin in the third decade.
David Sinclair: John, it seems that SIRT1 is nondiscriminatory in terms of mechanism. I am not surprised that activating an ancient, conserved defense pathway has such broad effects. It fits with the idea that we are mimicking caloric restriction, which prevents (in rodents and dogs, at least) most diseases of aging. It may take a while to know how SIRT1 is doing it, but it seems very powerful.
John Trojanowski: David, but if you speak in detail to investigators on these diseases, some assert that it is the toxic gain of function, as in tangles, plaques, and Lewy bodies, that drives neurodegeneration, while in HD, the field seems to argue the inclusions are protective and other mechanisms underlie degeneration distinct from brain amyloidoses. So, how would an intervention that ameliorates toxic gains of function in tangles promote the protective effects of aggregates in HD?
David Sinclair: All, we do not yet know how many targets SIRT1 has, but it could be dozens -from p53 and heat shock proteins to DNA repair. All I can say for sure is that the animal model data I have seen from various laboratories is impressive. David Sinclair: June, the stress molecules in the plant turn on stress pathways (e.g., the sirtuins) and the plant is stress-resistant. We believe that we (and most life forms) have evolved to pick up on the chemical stress cues produced by stressed plants, causing us to mount a defense response in anticipation of loss of food supply or other adversity. We see these molecules activate numerous pathways associated with better health and disease resistance; most of this is unpublished, but it is in accordance with the xenohormesis hypothesis. It means one small molecule can hit numerous beneficial targets, and it is not just luck; we evolved that way.
June Kinoshita: David, that is fascinating. Will there be a publication on this in the near future?
Greg Cole: David, the heat shock system seems to be upregulated with xenohormesis and it likely slows the rate of misfolded protein aggregate accumulation.
Gabrielle Strobel: David, this sounds fascinating but fairly non-specific. What is the cost to the organism of activating this stress response, especially long-term (i.e., side effects of such compounds)?
David Sinclair: Gabrielle, about long-term effects:
We have a study that is 2 years on now, having treated mice with a STAC, and there are no apparent ill effects, only benefits so far. We also know that SIRT1 is activated by caloric restriction, and that having this protein elevated for the life of the rodent is beneficial in a number of disease areas.
Sally Frautschy: I am interested in the possibility that omega-3 fatty acids may not be protective for those with ApoE4, as suggested by epidemiology. I am interested in the difference between DHA and eicosapentanoic acid (EPA) omega-3 fatty acids. We have only tested DHA from algae. I think there needs to be a clinical trial to test DHA plus EPA versus DHA alone. EPA competes for DHA incorporation in the membrane so it may prevent DHA replenishment. However, EPA has anti-platelet effects and is a better anti-inflammatory in the periphery, and may be better for heart disease prevention.
John Trojanowski: David Sinclair, can one get the same effects with red wine rich in resveratrol?
Gabrielle Strobel: David, one last question: Are resveratrol and other SIRT inducers in foods such as wine and pomegranate potent enough to have a neuroprotective effect merely through dietary changes?
Sally Frautschy: I, personally, will take the curry. We measure curcumin in brain and show that it is high enough to reduce oligomer aggregation. Has anyone measured pomegranate or resveratrol in the brain to see if dietary doses reduce aggregation of amyloid?
David Sinclair: John, I sincerely doubt wine has enough resveratrol. In the mouse studies done at Harvard and with our collaborators at NIH, we use pure compound and it is at higher concentrations than you can get from red wine. There is a company called Sirtris that I co-founded in 2004 which has found novel SIRT1 activators that could have far better effects than resveratrol.
Gabrielle Strobel: David Sinclair, are you specifically targeting AD with your preclinical assays of those compounds (other than the p25 mice)?
David Sinclair: Gabrielle, we have about 15 different experiments, mostly in the neurodegenerative area but also cancer, stem cells, aging, cardiovascular, metabolic. . . Lots of dollars are needed.
John Trojanowski: In general terms, one place to start is with some of the take-away messages from the Jedrziewski review of literature on lifestyle practices to reduce risk of dementia. Many of these practices come from studies by the folks here. They include lifestyles or activities that increase cognitive activity: education, exercise, avoiding head injury, good nutrition with a diet rich in antioxidants and that promotes low cholesterol. Are these agreed upon? Are there others not listed here?
Sam Sisodia: Environmental enrichment (EE) might be considered an analogue of several prospective and retrospective studies suggesting an important role for exercise and mental activity in reducing the risk for AD and cerebrovascular disease. Our microarray data have been quite informative and reveal upregulation of genes involved in neuroprotection, Aβ sequestration (transthyretin [TTR]), and synaptic plasticity. Indeed, our recent, unpublished data indicate that our AβPP/PS mice placed in a TTR+/− background show earlier onset of deposition and enhanced Aβ burden in older animals.
Gabrielle Strobel: Sam, I understand the transthyretin connection but did not get that entirely. What is the meaning? Too much iron in brain accelerates amyloid deposition?
Sam Sisodia: Gabrielle, it has nothing to do with iron. TTR is a known Aβ binding/sequestering protein. Its normal function in brain is not fully known, but it is expressed in the choroid at high levels. It is probably involved in moving highly lipophilic molecules across the blood-brain barrier (BBB), but it is still a mystery why it is so highly upregulated in mice that have EE. We also see very high expression in Tg2576 mice at 6 months [7] well before pathology. . . . Is this a protective mechanism to sequester toxic Aβ species?
Sally Frautschy: TTR is a thyroid hormone transport protein induced by fish oil. Dmitry Goldgaber shows it is important in clearing amyloid from brain [8] .
John Trojanowski: To the participants here, I ask if there is consensus around some of the briefly stated measures above or if there are disagreements or other activities to consider. Also, what research is needed to validate some of these strategies to reduce risk of dementia so they can be recommended to the public?
Lewis Kuller: I doubt whether any of the variables listed by John are really related to the etiology of dementia but probably just delay diagnosis. They are similar to risk factors for good health, prevention of heart disease, cancer, diabetes, and arthritis.
June Kinoshita: Lewis raises a central point. Why do the same risk factors pop up for all of these diseases of aging?
Dave Morgan: June, it is conceivable that they are modifying the overall rate of aging, and this larger process is setting the stage for disease.
Deborah Blacker: John (on the list of lifestyle factors) and Lewis, I agree. The best support is for those that clearly reduce cardiovascular risk (physical exercise, and cholesterol and weight reduction), and, of course, avoiding head injury is a good idea. I suspect education is very non-specific, and that mental activity may be a marker for education, and general physical and mental health. John Trojanowski: Yes, Lewis, these are all data from association studies, and they do not imply cause and effect, and the benefits do extend beyond brain aging or dementia. However, in the face of an obesity epidemic when folks like Jau Olshansky argue there will be a reversal in longevity trends, there still is a great need to demonstrate how these lifestyle activities might work and which can become preventatives rather than merely association findings [9, 10] .
Greg Cole: Lewis, since the risk factors for AD strongly overlap those for heart disease, and along with cancer, arthritis, and aging they all have chronic inflammatory components, it is quite possible that they do relate to etiology.
Deborah Blacker: Greg, I agree that the cardiovascular risk factors may have the strongest link to etiology, but the mechanism remains unclear.
Greg Cole: Deborah, there are likely multiple mechanisms of interest. At this point, all of the genetic and epidemiological risk factors seem to impinge on amyloid metabolism, but the details remain vague. It would be nice to know enough about mechanism to understand which of the protective strategies can be made to synergize.
Gabrielle Strobel: Greg, thanks, I was wondering the same thing. It seems that many of those factors affect amyloid metabolism. Is that really so, or does it merely appear to be so because people tend to check around the leading hypothesis first? Do studies such as Sam Sisodia's microarrays and David Sinclair's work with sirtuin inducers point to entirely different pathways?
Lewis Kuller: If cholesterol and exercise are important risk factors, the Japanese should have low rates.
Greg Cole: Lewis, it is true that one would expect lower rates based on environmental risk factors, but they live longer and do not die of cardiovascular disease (CVD), so the situation is complicated by competing causes, other diseases, and risk factor interactions. For example, in Japan ApoE4 seems to confer less risk than in Western populations. Why? Deborah Blacker: Lewis, but the Japanese have lots of high blood pressure. Do you recall overall level of cardiovascular risk? I thought it was relatively high.
June Kinoshita: Regarding Gabrielle's question, I was wondering the same thing. How many other things have people looked at in the various mouse experiments, for example, white matter pathology, inflammation, insulin signaling, etc.?
Deborah Blacker: Greg, I share your sense that the ApoE4 risk is complicated by competing risk and interactions, and do not know about the specifics of cardiovascular disease risk in Japan to support a strong hypothesis. One possibility would relate to minor strokes that might make an AD diagnosis less likely (even if AD pathology is indeed present).
Greg Cole: Deborah, the autopsy rate is very low in Japan, so it makes you wonder how many minor stroke cases have mixed etiology.
Deborah Blacker: Greg, I suspect it is high, since it is high here, and rates of pure vascular dementia are low.
Lewis Kuller: Greg, age-specific AD pathology or magnetic resonance imaging (MRI) and positron emission tomography (PET) findings should be different among older Japanese versus Americans, etc. Life expectancy for Japanese age 65-70 is not very different from that in the US. The key is to find populations which have both low rates of clinical AD and dementia and low prevalence of pathology and/or MRI and PET abnormalities and determine the unique characteristics of such populations, as was done for coronary heart disease (CHD), stroke, diabetes, and many cancers.
Lucy Boyd: Lewis, I agree completely. Regarding education and cognitive activity as preventative measures, if this is so, does anyone have an opinion on whether it is due to a distinct difference made in the brain by learning, or if there is more reserve to lose before symptoms are noted?
that would have to be addressed for you to be confident you had found one.
Bill Thies: Marcelle and Lewis, since there is little in the way of preventative trials in AD, is it possible we can do trials in AD in the traditional way like those prevention trials for cardiovascular (CV) disease. If we cannot, who has the next great methodology?
Deborah Blacker: Bill, the first big prevention trial, with a huge price tag, was halted because of risk. The vitamin E prevention trials with AD as secondary outcome were also halted. What would be next, and who will fund it? Anyone in this group?
Greg Cole: Bill, is it possible to try to get a prevention trial with an intervention likely to work for more than one disease of aging? For example, colon cancer, atherosclerosis, and AD all have inflammation as a significant risk factor. We are hoping that some type of polyphenolic antioxidant/nonsteroidal anti-inflammatory drug (NSAID) like curcumin or resveratrol could be used for more than one disease and have multiple agency sponsorship.
June Kinoshita: Greg's idea of trials aimed at slowing down general aging processes that affect risk for all kinds of chronic diseases of aging is interesting. How feasible is it, given that funders like to see impact on their specific diseases?
Deborah Blacker: Greg, this kind of thinking was behind the big vitamin E trials, too. It is a great idea, but there is reason for caution.
Bill Thies: Deborah, the results of AD prevention trials have been clear, so how do we do them faster and cheaper?
Deborah Blacker: Bill, doing them for mild cognitive impairment (MCI) was the way to do them faster and cheaper (I know, not cheap, but cheaper than the Alzheimer's Disease Antiinflammatory Prevention Trial (ADAPT), but the tradeoff is that you are not really doing prevention because the disease pathology is already in place.
John Trojanowski: Bill, there are so many potentially exciting ideas for intervention/prevention here, so how do we do what the March of Dimes did in the 1950s? Mobilize the American people to dedicate similar resources as those that cured polio to have a similar impact on aging-related neurodegenerative diseases?
Bill Thies: John, I do believe that one part of this is to begin a conversation with the public that lets them know we cannot solve the problem without their participation in clinical studies, both trials and natural history studies. If we can convince the public that they are a key part of finding the answers that are important to them, we will be part of the way to mobilization. June Kinoshita: Regarding faster and cheaper trials, we need antecedent biomarkers.
Deborah Blacker: John, great idea given the numbers involved and the level of fear. Can we pose this question to Marcelle, too, aware as we are that federal resources are thin, so we would still want moral support/matching funds?
Marcelle Morrison-Bogorad: Deborah, I would like to think that if a clinical trial (or two or three) were compelling, we would have additional non-NIH sponsors. But, however sponsored, we will probably have to go through pilot trials first to optimize all the methodology.
Lewis Kuller: Marcelle, I think you need to focus on geographic studies with imaging, and trials to prevent pathology using imaging and add-ons to trials, cardiovascular disease, etc.
Lucy Boyd: I believe the statins hold promise as ancillary prevention.
John Trojanowski: We also need a campaign like the March of Dimes that mobilized funds, but also volunteers in communities across the U.S. to eradicate a disease that, while terrible, does not begin to have the horrific consequences AD will have in the coming decades.
Sally Frautschy: John, yes, we need more campaigning. Trials with the strongest rationale (ibuprofen) cannot be done because of lack of money. We had to do naproxen because that company paid for placebo. Thus, we need donors to help complete costs of trials with the strongest rationale.
Greg Cole: Marcelle, is there any kind of cognitive testing that could be done with Internet testing at libraries under the supervision of a librarian? They are all connected.
Marcelle Morrison-Bogorad: Greg, I do not know. I will ask.
Deborah Blacker: Marcelle, pilot trials sound like a great option to help keep costs down. I hope the options for trials are compelling. We may have to kiss a lot of frogs, and pay for the privilege before we find our prince.
Sam Sisodia: Adding to John's notion, it is remarkable that over 25 percent of the US population is considered obese, and in Illinois, it is a staggering 28 percent. . . and with the increasing tightening of local budgets there is less exercise/gym periods in public schools (now only 45 minutes a week in Chicago public schools), so I would suggest that the first thing we instruct the public to do is to get off their sofas and eat fewer greasy burgers, etc. Prevention is really very simple and we need to educate the public, and under the auspices of the federal, state, and local governments.
Gabrielle Strobel:
We have come to the end of the hour. Thanks to everyone.
